Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.1% - Here's Why

Key Points

• Gain Therapeutics shares rose about 1.1% to $1.90 (intraday high $1.95) on roughly 561,104 shares traded, essentially in line with average volume.
• Analysts' consensus is a “Moderate Buy” (four Buys, one Sell) with a $8.50 average price target, although Weiss Ratings recently reaffirmed a sell (d-) on the stock.
• The company is a clinical-stage biopharma developing GT-022 for Gaucher disease and reported Q1 EPS of ($0.11) beating estimates; it has a market cap of about $81M, negative P/E, and high liquidity ratios (quick/current ratio 6.63).

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report)'s share price rose 1.1% during trading on Monday . The company traded as high as $1.95 and last traded at $1.90. Approximately 561,104 shares changed hands during mid-day trading, an increase of 0% from the average daily volume of 558,324 shares. The stock had previously closed at $1.88.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Gain Therapeutics in a research note on Friday, April 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $8.50.

Gain Therapeutics Stock Performance

The stock has a 50 day moving average of $2.16 and a 200 day moving average of $2.39. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $81.04 million, a price-to-earnings ratio of -3.11 and a beta of 0.15.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. As a group, analysts predict that Gain Therapeutics, Inc. will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Apollon Wealth Management LLC increased its holdings in Gain Therapeutics by 33.7% in the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company's stock worth $51,000 after purchasing an additional 6,675 shares in the last quarter. Millennium Management LLC bought a new stake in Gain Therapeutics in the fourth quarter worth approximately $45,000. Engineers Gate Manager LP bought a new stake in Gain Therapeutics in the fourth quarter worth approximately $47,000. OMERS ADMINISTRATION Corp bought a new stake in Gain Therapeutics in the fourth quarter worth approximately $120,000. Finally, Marshall Wace LLP increased its holdings in Gain Therapeutics by 849.3% in the fourth quarter. Marshall Wace LLP now owns 1,662,293 shares of the company's stock worth $5,353,000 after purchasing an additional 1,487,186 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.